1. Bantis, L. E., Nakas, C. T. and Reiser, B. (2014). Construction of confidence regions in the ROC space after the estimation of the optimal Youden index-based cut-off point. Biometrics 70, 212-223.
2. CHMP. (2009). Appendix 1 to the guideline on clinical evaluation of diagnostic agents (CPMP/EWP/1119/98 REV. 1) on imaging agents (Doc. Ref. EMEA/CHMP/EWP/ 321180/2008). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003581.pdf [18 February 2016].
3. Clark, C. M., Schneider, J. A., Bedell, B. J., Beach, T. G., Bilker, W. B., Mintun, M. A., Pontecorvo, M. J., Hefti, F., Carpenter, A. P., Flitter, M. L., Krautkramer, M. J., Kung, H. F., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Sabbagh, M. N., Sadowsky, C. H., Reiman, E. M., Zehntner, S. P. and Skovronsky, D. M. (2011). Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283.
4. DerSimonian, R. and Laird, N. (1986). Meta-Analysis in Clinical Trials. Controlled Clinical Trials 7, 177-188.
5. FDA. (2004). Guidance for industry. Developing medical imaging drug and biological products. Part 3: design, analysis, and interpretation of clinical studies. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071604.pdf [18 February 2016].